Nanofix (Human Coagulation Factor Ix)

Human Coagulation Factor IX, the active ingredient in Nanofix, is a blood coagulation factor presented as a sterile intravenous solution for intravenous use. It treats hemophilia B and acquired factor IX deficiency by replacing the missing protein in patients.

GNH USA supplies Nanofix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Nanofix is used to replace deficient factor IX in the intrinsic coagulation pathway for several bleeding disorders.

- Hemophilia B: restores normal clotting and reduces bleeding episodes in patients with congenital factor IX deficiency. - Acquired factor IX deficiency: provides temporary replacement to control bleeding caused by acquired loss of factor IX. - Peri‑operative management in hemophilia B: ensures adequate haemostasis during surgery or invasive procedures.

Nanofix may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Fever or chills - Headache - Nausea or vomiting - Mild infusion site erythema - Transient increase in blood pressure - Mild fatigue

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Development of inhibitors (antibodies) to factor IX - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Hemolysis or renal impairment - Severe hypotension during infusion - Viral transmission (theoretical risk with plasma‑derived products).

Before using Nanofix, consider the following safety measures.

- Screening: test for inhibitors to factor IX prior to initiation. - Monitoring: observe patients during and after infusion for signs of allergic reaction. - Concomitant therapy: avoid simultaneous use of other clotting factor concentrates unless medically indicated. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk; data are limited. - Renal or hepatic impairment: adjust monitoring frequency as these conditions may affect clearance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Nanofix can interact with other agents that affect haemostasis or immune response.

Major Interactions (Avoid): - Antifibrinolytics (e.g., tranexamic acid) combined with high‑dose factor IX may increase thrombosis risk. - Other clotting factor concentrates administered concurrently without specialist guidance.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., rituximab) may alter inhibitor development risk. - Antibiotics such as beta‑lactams that can cause hypersensitivity may increase allergic reaction likelihood. - Heparin or low‑molecular‑weight heparin: monitor coagulation parameters closely when used together.